印度Shantha Biotechnics 
印度疫苗生产商Shantha公司总部设在印度的海德拉巴,从事几种重要疫苗的开发,生产及销售.Shantha设施先进,企业管理达到国际先进水平.2009年8月31日,赛诺菲巴斯德通过收购梅里埃联盟在法国的分公司ShanH正式控股Shantha,ShanH拥有Shantha的多数股权.Shantha与多个国际组织合作,向亚太地区,非洲及拉丁美洲大型的国际市场供货.1997年,Shantha将SHANVAC-B 疫苗投放市场,这是Shantha在印度生产的首个重组乙肝疫苗.其它如SHANVAC-B ,SHANTETRA (白喉,百日咳,破伤风及乙肝联合疫苗), SHAN5 (白喉,百日咳,破伤风,b型流感嗜血杆菌及乙肝联合疫苗),以及SHANTT (破伤风类毒素)为世界卫生组织(WHO)预审合格疫苗,可向世界各地的联合国机构供货.Shantha还有一系列重要的疫苗处于研发阶段.
     
A pioneer in the field of biotechnology, Shantha Biotechnics is the first Indian company to develop, manufacture and market a recombinant human healthcare product in India. We are committed to breaking new ground in modern biotechnology to address critical healthcare needs of the developing world.

Shantha is currently focusing its R&D efforts in the development of generic biologicals, novel therapeutic antibodies, proteins and vaccines. Shantha conducts exploratory research in the fields of Oncology, Infectious Diseases and Platform technologies.

SHANVAC- B is the first Indian Hepatitis-B vaccine to be pre-qualified by WHO, Geneva, for supplying to UN agencies globally. Today, Shantha caters to major international markets including Asia-Pacific, Africa, CIS and Latin America in addition to supra nations like UNICEF and PAHO.

To make cutting edge technologies available to the common man Shantha is constantly exploring the possibilities of partnerships to facilitate innovations in research and development.

A deep sense of commitment and a tradition of excellence have characterized Shantha’s journey thus far and have placed it in the forefront of exciting scientific ventures. However, there are still bigger oceans to be crossed and farther shores to be reached.

Shantha has also obtained WHO-Geneva Pre-qualification for its combination vaccine of DPT+ Hepatitis-B vaccine “ SHANTETRA, enabling supplies to UN Agencies.